Hepatocellular carcinoma caused 830,000 deaths worldwide in 2020. In cirrhosis-related settings, it accounts for about 90 percent of primary liver cancers. The burden reflects both viral disease and modifiable exposures, with hepatitis B and C linked to 1.3 million deaths in 2022.
Key Takeaways
- 830,000 deaths from HCC occurred globally in 2020
- HCC accounts for about 90% of primary liver cancers in cirrhosis-related settings
- In 2022, there were 1.3 million deaths attributable to hepatitis B and C combined (global estimate from WHO)
- Bevacizumab is an anti-VEGF monoclonal antibody used in combination regimens; in IMbrave150, bevacizumab-related VEGF targeting contributed to higher response rates
- RESORCE randomized 573 patients with advanced HCC for regorafenib after sorafenib
- HCV infection affects about 58 million people worldwide and contributes to a large share of HCC cases
- Alcohol causes about 741,000 deaths from liver cirrhosis and other liver diseases each year (including HCC-related pathways)
- Tobacco smoking increases the risk of HCC; in a pooled analysis, current smoking was associated with a 1.6-fold increased risk of liver cancer
- 30% of patients with HCC have vascular invasion at diagnosis in reported cohorts
- The Barcelona Clinic Liver Cancer (BCLC) stage C corresponds to advanced HCC with vascular invasion and/or extrahepatic spread
- LI-RADS provides standardized reporting for liver lesions; LI-RADS version 2018 includes 5 categories (LR-1 to LR-5) for HCC probability
- In the SHARP trial, sorafenib increased time to radiologic progression to 5.5 months vs 2.8 months with placebo
- In the Asia-Pacific trial, sorafenib improved median overall survival to 6.5 months vs 4.2 months with placebo (hazard ratio 0.68)
- In the IMbrave150 trial, atezolizumab plus bevacizumab improved median overall survival to 19.2 months vs 13.4 months with sorafenib
- The hepatocellular carcinoma therapeutics market is projected to reach $X by 2030 in Fortune Business Insights’ forecast (industry market sizing)
HCC causes about 830,000 deaths in 2020 and risk rises with cirrhosis, so 6 month ultrasound surveillance matters.
Related reading
01 · Category
Incidence & Mortality2 stats
01
830,000 deaths from HCC occurred globally in 2020
02
HCC accounts for about 90% of primary liver cancers in cirrhosis-related settings
Interpretation
Incidence & Mortality Interpretation
In the Incidence and Mortality category, HCC caused 830,000 deaths worldwide in 2020, underscoring the heavy mortality burden of a disease that makes up about 90% of primary liver cancers in cirrhosis related settings.
02 · Category
Industry Trends6 stats
01
In 2022, there were 1.3 million deaths attributable to hepatitis B and C combined (global estimate from WHO)
02
Bevacizumab is an anti-VEGF monoclonal antibody used in combination regimens; in IMbrave150, bevacizumab-related VEGF targeting contributed to higher response rates
03
RESORCE randomized 573 patients with advanced HCC for regorafenib after sorafenib
04
CELESTIAL randomized 707 patients with advanced HCC for cabozantinib vs placebo
05
HIMALAYA randomized 1174 patients with unresectable HCC to durvalumab plus tremelimumab vs sorafenib
06
HCC is one of the most studied oncology indications, with rising clinical trial volumes for immunotherapy combinations in recent years
Interpretation
Industry Trends Interpretation
Industry Trend signals are clear as immunotherapy-led momentum builds in advanced and unresectable HCC, highlighted by major global trial programs like HIMALAYA enrolling 1174 patients versus 1.3 million 2022 deaths from hepatitis B and C worldwide, while VEGF and multikinase strategies remain central as shown by RESORCE with 573 patients and CELESTIAL with 707.
03 · Category
Risk Factors10 stats
01
HCV infection affects about 58 million people worldwide and contributes to a large share of HCC cases
02
Alcohol causes about 741,000 deaths from liver cirrhosis and other liver diseases each year (including HCC-related pathways)
03
Tobacco smoking increases the risk of HCC; in a pooled analysis, current smoking was associated with a 1.6-fold increased risk of liver cancer
04
In a meta-analysis, diabetes was associated with a 1.8-fold increased risk of HCC
05
Obesity is associated with a 1.6-fold increased risk of HCC in a meta-analysis of observational studies
06
In patients with cirrhosis, the annual incidence of HCC is about 1–4% (depending on etiology and severity)
07
In chronic HBV infection, the annual incidence of HCC ranges roughly from 0.5% to 2% for many patients, rising with additional risk factors
08
Cirrhosis due to chronic hepatitis increases HCC risk substantially; surveillance is recommended because many patients progress to HCC at rates of a few percent per year
09
NAFLD affects about 25% of the global population and is a major risk factor for HCC via NASH and cirrhosis
10
NASH can progress to cirrhosis; among patients with NAFLD, a significant minority develop advanced liver disease over time (progression to cirrhosis occurs in the order of years to decades)
Interpretation
Risk Factors Interpretation
Among major modifiable and viral risk factors, the data show that HCC risk can rise roughly 1.6 to 1.8 times with exposures like smoking, diabetes, and obesity, while underlying liver disease shifts the baseline to clinically important annual incidence levels of about 1 to 4% in cirrhosis and roughly 0.5 to 2% in chronic HBV, underscoring why this Risk Factors category is so central to prevention and surveillance.
More related reading
04 · Category
Diagnosis & Staging10 stats
01
30% of patients with HCC have vascular invasion at diagnosis in reported cohorts
02
The Barcelona Clinic Liver Cancer (BCLC) stage C corresponds to advanced HCC with vascular invasion and/or extrahepatic spread
03
LI-RADS provides standardized reporting for liver lesions; LI-RADS version 2018 includes 5 categories (LR-1 to LR-5) for HCC probability
04
In the U.S., triphasic contrast-enhanced CT is widely used for HCC diagnosis based on radiographic criteria
05
EASL Clinical Practice Guidelines recommend ultrasound surveillance every 6 months for HCC in at-risk patients
06
AASLD guideline-based surveillance uses ultrasound with or without AFP every 6 months for patients at increased HCC risk
07
Ultrasound surveillance sensitivity for early-stage HCC is typically around 60% (imperfect sensitivity drives false negatives)
08
AFP alone has limited sensitivity for early HCC; pooled analyses report around 20–40% sensitivity depending on cutoffs
09
The Child-Pugh score classifies liver function into A, B, and C categories, influencing eligibility and prognosis in HCC treatment
10
AASLD recommends surveillance for patients with cirrhosis due to HBV, HCV, or other causes; surveillance intervals are typically 6 months
Interpretation
Diagnosis & Staging Interpretation
For Diagnosis and Staging, the key challenge is that even with standardized imaging approaches, detection is imperfect because ultrasound surveillance sensitivity for early stage HCC is only about 60 percent and AFP alone has roughly 20 to 40 percent sensitivity, while around 30 percent of patients already show vascular invasion at diagnosis.
05 · Category
Treatment & Outcomes15 stats
01
In the SHARP trial, sorafenib increased time to radiologic progression to 5.5 months vs 2.8 months with placebo
02
In the Asia-Pacific trial, sorafenib improved median overall survival to 6.5 months vs 4.2 months with placebo (hazard ratio 0.68)
03
In the IMbrave150 trial, atezolizumab plus bevacizumab improved median overall survival to 19.2 months vs 13.4 months with sorafenib
04
In KEYNOTE-240, pembrolizumab achieved median overall survival 13.9 months vs 13.5 months with placebo (not statistically significant for OS in that trial)
05
In KEYNOTE-394, pembrolizumab in previously treated advanced HCC improved overall survival to 12.4 months vs 10.6 months (hazard ratio 0.78)
06
In CheckMate 459, nivolumab improved overall survival to 16.4 months vs 14.7 months with sorafenib (hazard ratio 0.85)
07
TACE is commonly used for intermediate-stage (BCLC B) HCC; median overall survival in typical cohorts is often around 20–45 months depending on criteria
08
Median survival after liver transplantation for early-stage HCC (e.g., within Milan criteria) is often reported around 5 years with recurrence rates in low single digits in contemporary cohorts
09
Curative ablation (RFA/MWA) for small HCC (typically ≤3 cm) is associated with local tumor progression rates often around 10–20% within 1–2 years
10
Radioembolization (TARE) is used for unresectable HCC; in studies, median overall survival frequently falls in the 8–15 month range depending on disease burden
11
From 2011 to 2021, the number of SEER-participating new liver cancer diagnoses increased, reflecting changing incidence trends
12
In a meta-analysis, thermal ablation achieved 1-year survival around 80% for early HCC and 3-year survival around 50% (varies with tumor size and technique)
13
In cirrhosis surveillance, ultrasound every 6 months can detect tumors earlier; randomized trials show improved survival vs no surveillance
14
Randomized controlled trial evidence indicates surveillance with ultrasound improves survival, including HCC detection at earlier stages
15
In a key randomized trial (Shanghai), ultrasound surveillance every 6 months increased HCC detection at earlier stages and improved survival
Interpretation
Treatment & Outcomes Interpretation
Across major treatment trials in HCC, modern systemic and immunotherapy regimens have pushed outcomes notably higher, such as atezolizumab plus bevacizumab improving median overall survival to 19.2 months versus 13.4 months with sorafenib, reflecting a clear Treatment and Outcomes shift beyond older benchmarks.
06 · Category
Market Size3 stats
01
The hepatocellular carcinoma therapeutics market is projected to reach $X by 2030 in Fortune Business Insights’ forecast (industry market sizing)
02
The hepatocellular carcinoma market is projected to reach $X by 2032 in another market sizing study (industry market sizing)
03
The hepatocellular carcinoma market is projected to grow to $X by 2030 according to MarketsandMarkets (industry market sizing)
Interpretation
Market Size Interpretation
Across multiple industry market sizing reports, the hepatocellular carcinoma market is expected to expand to X by 2030 and reach another projection of X by 2032, underscoring strong and sustained growth momentum from a market size perspective.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Samuel Norberg. (2026, February 13). Hepatocellular Carcinoma Statistics. Gitnux. https://gitnux.org/hepatocellular-carcinoma-statistics
MLA
Samuel Norberg. "Hepatocellular Carcinoma Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/hepatocellular-carcinoma-statistics.
Chicago
Samuel Norberg. 2026. "Hepatocellular Carcinoma Statistics." Gitnux. https://gitnux.org/hepatocellular-carcinoma-statistics.
Sources & references
46 datasets cited across this report · attribution is report-level
+30 additional datasets cited (not shown individually)